Abstract

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses upadacitinib (Rinvoq), 15 mg, 30 mg, and 45 mg once daily, extended-release tablets, oral.
 Indication: For the treatment of adult patients with moderately to severely active Crohn disease who have demonstrated prior treatment failure, i.e., an inadequate response, loss of response, or intolerance to at least 1 conventional and/or biologic therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
